Пищеварительная система при антипсихотической терапии (обзор литературы). Часть VI: ятрогенная патология печени (эффект атипичных антипсихотиков)
Аннотация
Антипсихотические препараты, широко использующиеся в медицинской практике, обладают обширным спектром негативных побочных эффектов, в том числе действующих на органы системы пищеварения. В заключительной части предлагаемого обзора рассмотрена патология печени, ассоциированная с приемом отдельных конкретных антипсихотических препаратов второго поколения.
Список литературы
1. A case report of olanzapine-induced hypersensitivity syndrome / A. Raz, R. Bergman, O. Eilam [et al.] // Am. J. Med. Sci.-2001.- Vol. 321, N2.- P. 156-158. doi: 10.1097/00000441-200102000-00008.
2. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study / D. E. Addington, A. Labelle, J. Kulkarni [et al.] // Can. J. Psychiatry.- 2009.- Vol. 54, N 1.- P. 46-54. doi: 10.1177/070674370905400108.
3. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study / N. Atasoy, A. Erdogan, I. Yalug [et al.] // Prog. Neuropsychopharmacol. Biol. Psychiatry.- 2007.- Vol. 31, N6.- P. 1255-1260. doi: 10.1016/j.pnpbp.2007.05.005.
4. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study / M. Arato, R. O'Connor, H. Y. Meltzer[et al] / / Int. Clin. Psychopharmacol. - 2002.- Vol. 17, N5.- P. 207-215.
5. Acute cholestatic hepatitis probably associated with risperidone / F. Llinares Tello, C. Hernandez Prats, N. Bosacoma Ros[et al.] // Int. J. Psychiatry Med.- 2005.- Vol. 35, N2.- P. 199-205. doi: 10.2190/5XRB-D 2XX-X8AH-32KB.
6. Acute drug-induced hepatitis during aripiprazole monotherapy: a case report / J. Kornischka, J. Cordes, C. Engelke [et al.] / / J. Pharmacovigil.- 2016.- Vol. 4, N2.- Art. 201. doi:10.4172/2329-6887.1000201.
7. [Acute hepatocellular lesion after successive exposure to clozapine and olanzapine in a patient with chronic hepatitis C infection] / R. Gomez Espn, I. Sanchez Quiles, H. Hallal[et al.] / / Gastroenterol. Hepatol.-2009.- Vol. 33, N2.- P. 150-152. doi: 10.1016/j.gastrohep.2009.08.001
8. Akta$ S, Bakir M. G.T., Kaya B. Toxic hepatitis development due to clozapine treatment for schizophrenia: case presentation // Turk. J. Psychiatry.- 2015.- Vol. 26, Suppl 1.- Р. 47.
9. Al Mutairi F., Dwivedi G., Al Ameel T. Fulminant hepatic failure in association with quetiapine: a case report // J. Med. Case Rep.- 2012.- Vol. 6, N 1.- P. 418. doi: 10.1186/1752-1947-5^18.
10. Antipsychotic Agents. [Электронный ресурс].- URL: http://livertox.nih.gov/AntipsychoticAgents. htm (дата обращения: 15.10.2016).
11. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications / C. Tek, S. Kucukgoncu, S. Guloksuz [et al.] // Early Interv. Psychiatry.- 2015.- Vol. 10, N3.- P. 193-202. doi: 10.1111/eip.12251.
12. Aripiprazole. [Электронный ресурс].- URL: http://livertox.nlm.nih.gov/Aripiprazole.htm (дата обращения: 15.10.2016).
13. [Autoimmune hepatitis after risperidone-induced cholestatic hepatitis] / M. L. Legaz Huidobro, P. Gonzalez Carro, F. Perez Roldan [et al.] // Gastroenterol. Hepatol.- 2005.- Vol. 28, N3.- P. 135-136. doi: 10.1157/13072013.
14. AstraZeneca. Seroquel (quetiapine fumarate).- 2003. [Электронный ресурс].- URL: http://www. accessdata.fda.gov/drugsatfda_docs/la-bel/2009/022047s011s 016s017s019s022lbl.pdf. (дата обращения: 21.02.2016).
15. Balestrieri M., Vampini C., Bellantuono C. Efficacy and safety of novel antipsychotics: a critical review // Hum. Psychopharmacol.- 2000.- Vol. 15, N 7.- P. 499-512. doi: 10.1002/1099-1077(200010) 15:7<499:: AID-HUP194>3.0.C0; 2-3.
16. Beasley C.M. Jr., Tollefson G.D., Tran P. V. Safety of olanzapine // J. Clin. Psychiatry.- 1997.- Vol. 58, Suppl 10.- P. 13-17.
17. Benazzi F. Risperidone-induced hepatotoxicity // Pharmacopsychiatry.- 1998.- Vol. 31, N6.- P. 241. doi:10.1055/s-2007-979337.
18. Bile ductopenia following therapy with sulpiride / D. Villari, F. Rubino, F. Corica [et al.] // Virchows Arch.- 1995.- Vol. 427, N2.- P. 223-226.
19. Bristol-Myers Squibb. Abilify (aripiprazole): EMA summary of product characteristics.- 2016. [Электронный ресурс]. - URL: http://www. ema.europa.eu/docs/en_GB/document_library/ EPAR_-_Product_Information/human/ 000471/ WC500020170.pdf. (дата обращения: 15.02.2016).
20. Case study: risperidone-induced hepatotoxicity in pediatric patients / S. Kumra, D. Herion, L. K. Jacobsen [et al.] // J. Am. Acad. Child. Adolesc. Psychiatry.- 1997.- Vol. 36, N5.- P. 701-705. doi: 10.1097/00004583-199705000-00022.
21. Chaplin A. C., Curley M. A., Wanless I. R. Re: Recent case report of clozapine-induced acute hepatic failure: letter.- Can. J. Gastroenterol.- 2010.- Vol. 24, N 12.- P. 739-740.
22. Clozapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Clozapine.htm (дата обращения: 15.10.2016).
23. [Clozapine-induced cholestatic jaundice: a case report] / G. Dorta, R Siebenmann, P. Fröhli [et al.] // Z. Gastroenterol.- 1989.- Vol. 27, N 7.- 388-390.
24. [Clozapine-induced cholestatic liver lesions. A case study] / G. Schmidt, G. Börsch, K.-M. Müller [et al.] // Dtsch. med. Wschr.- 1987.- Vol. 112.- P. 844-846. doi: 10.1055/s-2008-1068152.
25. Clozapine-induced fatal fulminant hepatic failure: a case report/ A. Chang, D.S. Krygier, N. Chatur[et al.] // Can. J. Gastroenterol.-2009.- Vol. 23, N5.- P. 376-378. doi: 10.1007/978-3-540-85705-1_38.
26. [Clozapine-induced toxic hepatitis] / J. T. Larsen, S. V. Clemensen, N. A. Klitgaard [et al.] // Ugeskr. Laeger.- 2001.- Vol. 163.- P. 2013-2014.
27. Clozapine-induced toxic hepatitis with skin rash / S. Y. Fong, K.L. Au Yeung, J. M. Tosh [etal.] // J. Psychopharmacol.- 2005.- Vol. 19, N 1.- P. 107. doi: 10.1177/0269881105047287.
28. Clozapine rechallenge after marked liver enzyme elevation: letter/ A. E. Eggert, M. L. Crismon, P. G. Dorson [et al.] // J. Clin. Psychopharmacol.- 1994.- Vol. 14, N6.- P. 425-426.
29. Clozapine toxicity and hepatitis / C. A. Brown, S. Telio, C.A. [etal.] // J. Clin. Psychopharmacol.- 2013.- Vol. 33, N4.- P. 570-571. doi: 10.1097/ JCP.0b013e3182946586.
30. Conley R. R., Meltzer H. Y. Adverse events related to olanzapine // J. Clin. Psychiatry.- 2000.- Vol. 61, Suppl 8.- P. 26-29.
31. Cordeiro Q. Jr., Elkis H. Pancreatitis and cholestatic hepatitis induced by risperidone: letter / / J. Clin. Psychopharmacol.- 2001.-Vol. 21, N5.- P. 529-530.
32. Dara L., Liu Z. X., Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications // Liver Int.- 2016.- Vol. 36, N2.- P. 158-165. doi: 10.1111/liv.12988.
33. Double-blind comparison of ziprasidone and risperidone in the treatment of Chinese patients with acute exacerbation of schizophrenia / H. Zhang, H. Li, L. Shu [et al] // Neuropsychiatr. Dis. Treat.- 2011.- Vol. 7, N 1.- P. 77-85. doi: 10.2147/NDT.S 16664.
34. Drug rash with eosinophilia and systemic symptoms (DRESS syndrome): letter / J. S. Gordon, K. M. Neyman, R. D. Wells [et al.] // Cutis.-2012.- Vol. 89, N4.- P. 180-182.
35. Drug-induced liver injury: hepatotoxicity of quetiapine revisited / A. Shpaner, W. Li, V. Ankoma- Sey[et al.] //Eur. J. Gastroenterol. Hepatol.- 2008.- Vol. 20, N 11.- P. 1106-1109. doi: 10.1097/ MEG.0b013e3282f8e3a0.
36. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia / S. W. Kim, I. S. Shin, J. M. Kim [et al.] // Clin. Neuropharmacol.-2010.- Vol. 33, N3.- P. 121-125. doi: 10.1097/WNF.0b013e3181d52b85. Медицинский алфавит № 40 / 2017, том № 4. Практическая гастроэнтерология E-mail: medalfavit@mail.ru
37. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia - a retrospective study of 387 patients / D. Naber, M. Leppig, R. Grohmann [et al.] // Psychopharmacology (Berl.).- 1989.- Vol. 99, Suppl- P. S73-S76.
38. El Hajj I., Sharara A.I,, Rockey D. C. Subfulminant liver failure associated with quetiapine // Eur. J. Gastroenterol. Hepatol.- 2004.- Vol. 16, N12.- P. 1415-1418.
39. European Medicines Agency. EPAR summary for the public: paliperidone.- 2015. [Электронный ресурс].- URL: http://www.ema.europa.eu/ docs/en_GB/ document_library/EPAR_-_Product_I nformation/human/0040 66/WC500180640. pdf. (дата обращения: 21.02.2016).
40. Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity / B. Macfarlane, S. Davies, K. Mannan [et al.] / / Gastroenterology.- 1997.- Vol. 112, N5.- P. 1707-1709.
41. Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine / M. I. Naharci, N. Karadurmus, O. Demir [et al.] // Am. J. Psychiat.- 2011.- Vol. 168, N2.- P. 212-213. doi: 10.1176/ appi.ajp.2010.10091292.
42. Flanagan R. J. Side effects of clozapine and some other psychoactive drugs // Curr. Drug Saf.- 2008.- Vol. 3, N2.- P. 115-122. doi: 10.2174/157488608784529251.
43. Food and Drug Administration. Department of Health and Human Services. New molecular entity follow-up: aripiprazole.- 2008. [Электронный ресурс].- URL: http://www.fda.gov/down-loads/Drugs/DrugSafety/Post marketDrugSafety-InformationforPatientsandProviders/UCM185327. pdf. (дата обращения: 01.03.2016).
44. Food and Drug Administration. Psychopharmacology Drugs Advisory Committee. Briefing book: Serdolect (sertindole) tablets.-2009. [Электронный ресурс].- URL’ http://www.fda.gov/ohrms/ dockets/ac/09/briefing/ 2009-4424b1 -01 -FDA. pdf. (дата обращения: 20.03.2016).
45. Fuller M. A., Simon M. R., Freedman L. Risperidone-associated hepatotoxicity // J. Clin. Psychopharmacol.- 1996.- Vol. 16, N 1.- P. 84-85.
46. Gaertner H. J., Fischer E., Hoss J. Side effects of clozapine // Psychopharmacology (Berl.).- 1989.- Vol. 99, Suppl 1.- P. S 97-S 100.
47. Haberfellner E. M., Honsig T. Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics // J. Clin. Psychiatry.- 2003.- Vol. 64, N7.- P. 851.
48. Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment / W. C. Wirshing, D. Ames, S. Bisheff [et al.] // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N2.- P. 120-121.
49. Hepatic safety of atypical antipsychotics: current evidence and future directions / M. Slim, I. Medina-Caliz, A. Gonzalez-Jimenez [et al.] // Drug Saf.- 2016.- Vol. 39, N 10.- P. 925-943. doi: 10.1007/s40264-016-0436-7.
50. [Hepatic tolerance of atypical antipsychotic drugs] / G. Dumortier, W. Cabaret, L. Stamatiadis [et al.] // Encephale.- 2002.- Vol. 28, N 6, Pt 1.- P. 542-551.
51. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment / J. Thompson, K. N. Chengappa, C. B. Good [et al.] // Int. Clin. Psychopharmacol.- 1998.- Vol. 13, N2.- P. 95-98.
52. Hepatotoxicity of clozapine / M. Hummer, M. Kurz, I. Kurzthaler[et al.] // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N4.- P. 314-317.
53. Histological evaluation of the role of atypical antipsychotic drugs in inducing non-alcoholic fatty liver disease in adult male albino rats (light and electron microscopic study). / H. M. Soliman, H. M. Wagih, S. A. Algaidi [et al.] // Folia Biol. (Praha).- 2013.- Vol. 59, N5.- P. 173-180.
54. Hung C. C., Wei I. H., Huang C. C. Late-onset cholestatic hepatitis induced by olanzapine in a patient with schizophrenia // Prog. Neuropsycho-pharmacol. Biol. Psychiatry.-2009.- Vol. 33, N8.- P. 1574-1575. doi: 10.1016/j.pnpbp.2009.09.011.
55. Jadallah K. A., Limauro D. L., Colatrella A. M. Acute hepatocellular-cholestatic liver injury after olanzapine therapy // Ann. Intern. Med.- 2003.- Vol. 138, N4.- P. 357-358.
56. Kang S. H., Lee J. I. Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment // Clin. Psychopharmacol. Neurosci. - 2013.- Vol. 11, N2.- P. 103-105. doi: 10.9758/cpn.2013.11.2.103.
57. Kolpe M., Ravasia S. Effect of olanzapine on the liver transaminases // Can. J. Psychiatry.- 2003.- Vol. 48, N 3.- P. 210. doi: 10.1177/070674370304800313.
58. Landau J., Martin A. Is liver function monitoring warranted during risperidone treatment? // J. Am. Acad. Child Adolesc. Psychiatry.- 1998.- Vol. 37, N 10.- P. 1007-1008.
59. Larry D., Ripault M. P. Hepatotoxicity of psychotropic drugs and drugs of abuse / / Drug-induced liver disease / N. Kaplowitz, L. D. DeLeve (eds.).- 3rd ed.- Amsterdam: Elsevier, 2013.- P. 447-462.
60. Lin C. H., Liu C.M., Huang W. L. Quetiapine-induced hepatocellular damage // Psychosomatics.- 2012.- Vol. 53, N6.- P. 601-602. doi: 10.1016/j.psym.2012.06.001.
61. [Liver cell necrosis during administration of clozapine] / J. E. Hovens, L. M. Vogtländer, H. A. Verhoeve [et al.] // Ned. Tijdschr. Geneeskd.- 1994.- Vol. 138, N7.- P. 363-365.
62. Liver function tests in children and adolescents receiving risperidone treatment for a year: a longitudinal, observational study from Turkey / M. G. Karaman, A. Erdogan, E. Tufan [et al.] // Int. J. Psychiatry. Clin. Pract.- 2011.- Vol. 15, N3.- P. 204-208. doi: 10.3109/13651501.2011.582537.
63. Liver toxicity due to olanzapine: letter / J. L. Dominguez-Jimenez, J. J. Puente-Gutierrez, E.M. Pelado-Garcia [et al.] // Rev. Esp. Enferm. Dig.- 2012.- Vol. 104, N 11.- P. 617-618. doi: 10.4321/S 1130-0108201200110001.
64. Luo D., McColl P., Walmsley R. Acute onset of ascites with clozapine-induced hepatitis // Intern. Med. J.- 2007.- Vol. 37, N3.- P. 204-205. doi:10.1111/j.1445-5994.2006.01300.x.
65. Mahapatra S, Belgrad J. L., Adeoye M. A. Psychotropic drug-related eosinophilia with systemic symptoms after acute caffeine ingestion // Pediatrics.- 2011.- Vol. 127, N 1.- P. e235-e238. doi: 10.1542/peds.2010-0374.
66. Management of clozapine-related hepatotoxicity / S. Keane, A. Lane, T. Larkin [et al.] // J. Clin. Psychopharmacol.- 2009.- Vol. 29, N6.- P. 606-607. doi: 10.1097/JCP.0b013e3181c163ef.
67. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature / A. Erdogan, N. Kocabasoglu, I. Yalug [et al.] // Int. J. Psychiatry. Med.- 2004.- Vol. 34, N 1.- P. 83-89. doi: 10.2190/44WA-WXF7-3UHA-FDV1.
68. Management of marked liver enzyme increase during olanzapine treatment: a case report and review of the literature / P. Manceaux, E. Constant, N. Zdanowicz [et al.] // Psychiatr. Danub.- 2011.- Vol. 23, Suppl. 1.- S 15-S 17.
69. Markowitz J. S., Grinberg R., Jackson C. Marked liver enzyme elevations with clozapine // J. Clin. Psychopharmacol.- 1997.- Vol. 17, N 1.- P. 70-71.
70. Marwick K. F., Taylor M., Walker S. W. Antipsychotics and abnormal liver function tests: systematic review // Clin. Neuropharmacol.- 2012.- Vol. 35, N5.- P. 244-253. doi: 10.1097/ WNF.0b013e31826818b6.
71. McCormack P. L. Olanzapine: in adolescents with schizophrenia or bipolar I disorder // CNS Drugs.- 2010.- Vol. 24, N 5.- P. 443-452. doi: 10.2165/11204430-000000000-00000.
72. Melzer E., Knobel B. Severe cholestatic jaundice due to sulpiride // Isr. J. Med. Sci.- 1987.- Vol. 23, N 12.- P. 1259-1260.
73. Metabolic syndrome in people with schizophrenia: a review / M. DE Hert, V. Schreurs, D. Vancampfort [et al.] // World Psychiatry.- 2009.- Vol.8, N 1.- P. 15-22.
74. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions / L. Urichuk, T. I. Prior, S. Dursun [et al.] // Curr. Drug Metab.- 2008.- Vol. 9, N5.- P. 410-8.
75. Nasrallah H.A., Tandon R. Efficacy, safety, and tolerability of quetiapine in patients with schizophrenia // J. Clin. Psychiatry.- 2002.- Vol. 63, Suppl 13.- Р. 12-20.
76. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperi done or olanzapine alone / C. U. Pae, H. K. Lim, T. S. Kim [et al.] // Int. Clin. Psychopharmacol.- 2005.- Vol. 20, N3.- P. 173-176.
77. Ohmoto K., Yamamoto S., Hirokawa M. Symptomatic primary biliary cirrhosis triggered by administration of sulpiride: letter // Am. J. Gastroenterol.- 1999.- Vol. 94, N 12.- P. 3660-3661. doi:10.1111/j.1572-0241.1999.01634.x
78. Olanzapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Olanzapine.htm (дата обращения: 15.10.2016).
79. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial / G. D. Tollefson, C. M. Beasley Jr., P. V. Tran [et al.] // Am. J. Psychiatry.- 1997.- Vol. 154, N4.- P. 457-465. doi: 10.1176/ ajp.154.4.457.
80. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial / C. M. Beasley Jr., G. Tollefson, P. Tran [et al.] // Neuropsychopharmacology.- 1996.- Vol. 14, N2.- P. 111-123. doi: 10.1016/0893-133X(95)00069-P.
81. Olanzapine versus placebo: results of a doubleblind, fixed-dose olanzapine trial / C. M. Beasley Jr., T. Sanger, W. Satterlee [et al.] // Psychopharmacology.- 1996.- Vol. 124, N 1-2.- P. 159-167.
82. Paulzen M., Orfanos S., Gründer G. Remission of drug-induced hepatitis after switching from risperidone to paliperidone // Am. J. Psychiatry.- 2010.- Vol. 167, N3.- P. 351-352. doi: 10.1176/ appi.ajp.2009.09081243.
83. Phillips E. J., Liu B. A., Knowles S. R. Rapid onset of risperidone-induced hepatotoxicity // Ann. Pharmacother. - 1998.- Vol. 32, N7-8.- P. 843-844. doi: 10.1345/a ph.18022.
84. Possible olanzapine-induced hepatotoxicity in a young Chinese patient / S. Y. Lui, S. Tso, M. Lam [et al.] // Hong Kong Med. J.- 2009.- Vol. 15, N 5.- P. 394-396.
85. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity / D. Telles-Correia, A. Barbosa, H. Cortez-Pinto [et al.] // World J. Gastrointest. Pharmacol. Ther.- 2017.- Vol. 8, N 1.- P. 26-38. doi: 10.4292/wjgpt.v8.i1.26.
86. Quetiapine. [Электронный ресурс].- URL: http://livertox.nih.gov/Quetiapine.htm (дата обращения: 15.10.2016).
87. Quetiapine-associated cholestasis causing lipoprotein- X and pseudohyponatraemia / J. A. Klinke, S. C. Shapira, E. Akbari [et al.] // J. Clin. Pathol.- 2010.- Vol. 63, N 8.- P. 741-743. doi: 10.1136/ jcp.2008.064063.
88. Radzik J., Grotthus B., Leszek J. [Disorder of liver functions in a schizophrenic patient after long-term risperidone treatment - case report] // Psychiatr. Pol.- 2005.- Vol. 39, N2.- P. 309-313.
89. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis / M. I. Lucena, N. Kaplowitz, H. Hallal [et al.] // J. Hepatol.- 2011.- Vol. 55, N4.- P. 820-827. doi: 10.1016/j.jhep.2010.12.041.
90. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses / I. Gaertner, K. Altendorf, A. Batra [et al.] // J. Clin. Psychopharmacol.- 2001.- Vol. 21, N2.- P. 215-222.
91. Retrospective study of hepatic enzyme elevations in children treated with olanzapine, divalproex, and their combination / J. Gonzalez-Heydrich, D. Raches, T. E. Wilens [et al.] // J. Am. Acad. Child Adolesc. Psychiatry.- 2003.- Vol. 42, N 10.- P. 1227-1233. doi: 10.1097/00004583200310000-00014.
92. Risperidone. [Электронный ресурс].- URL: http://livertox.nih.gov/Risperidone.htm (дата обращения: 15.10.2016).
93. Risperidone and liver function tests in children and adolescents: a short-term prospective study / A. Erdogan, N. Atasoy, H. Akkurt [et al.] // Prog. Neuropsychopharmacol. Biol. Psychiatry.- 2008.- Vol. 32, N3.- P. 849-857. doi: 10.1016/j. pnpbp.2007.12.032.
Рецензия
Для цитирования:
Волков В.П. Пищеварительная система при антипсихотической терапии (обзор литературы). Часть VI: ятрогенная патология печени (эффект атипичных антипсихотиков). Медицинский алфавит. 2017;4(40):33-37.
For citation:
Volkov V.P. Digestive system with antipsychotic therapy (literature review) Part VI: iatrogenic liver pathology (effect of atypical antipsychotics). Medical alphabet. 2017;4(40):33-37. (In Russ.)
Просмотров:
347
Послать статью по эл. почте 